All News

This benefit was primarily driven by significant reductions in nonfatal heart attacks and the need for revascularization procedures.

The study demonstrated that providing a combination of produce prescriptions, dietitian coaching, and artificial intelligence-optimized encouragement led to improved cardiovascular outcomes.

The biosimilar is approved for all indications of the reference product, including the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Ashley Chinchilla, PharmD, BCACP, presents on the persistence of vaccine hesitancy among patients and the powerful tools used to address it.

Darren Mensch, PharmD, BCPS, BCACP, joins to discuss his presentation at APhA 2026 titled “Quality Wars: The AI Awakens in Pharmacy Practice.”

As population-level introduction of pneumococcal conjugate vaccines has led to an increase in invasive disease, the development of higher-valency vaccines has become a primary solution.

Stefanie Ferreri, PharmD, BCACP, FCCP, FAPhA, presents on the increase of misinformation circulating among the public and how pharmacists can combat this phenomenon.

Sally Rafie, PharmD, BCPS, dives deeper into her APhA 2026 presentation titled “Lights, Camera, Access: Contraception Care at the Pharmacy.”

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, and Staci-Marie Norman, PharmD, CDCES, FAPhA, present on updates to the ADA Standards of Care in Diabetes.

The FDA approves removing the age requirement for epinephrine nasal spray (neffy) 1 mg, effectively allowing all children and adults who weigh 33 pounds.

These guidelines serve as a comprehensive guideline that prioritizes earlier intervention through lifestyle optimization and lower treatment targets for those at highest risk.

Awiqli represents a significant shift in the treatment landscape, potentially reducing the burden of basal insulin administration from 365 injections a year to 52.

A new study suggests that even though the profession is at a crossroads, the path toward improvement depends heavily on the setting in which a pharmacist practices.

Amid recent comments from FDA Commissioner Marty Makary, MD, MPH, that “everything should be OTC,” Mark Garofoli, PharmD, BCGP, CPE, CTTS, helps pharmacists understand what lies ahead.

Gretchen Garofoli, PharmD, BCACP, CTTS, FAPhA, provides her perspective on the back-and-forth stemming from the federal government regarding US vaccine guidelines.

Pharmacists can build trust in buprenorphine care, handle early refill red flags, and point patients to resources to help them with substance use disorder.

New Glycemia Risk Index data shows continuous glucose monitoring cuts hypo- and hyperglycemia risk in type 1 diabetes, giving pharmacists a faster way to estimate control.

Phase 3 data show a 6-valent Lyme vaccine cuts confirmed cases by 73%, paving the way for 2026 filings and new prevention options.

Gretchen Garofoli, PharmD, BCACP, CTTS, FAPhA, provides her perspectives on the federal vaccine overhaul and its recent reversal in a Massachusetts federal court.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, dives deeper into recent comments from the FDA commissioner and what they mean for OTC medication access.

Harm reduction for pharmacists can include person-first language and stigma-free naloxone counseling that keeps patients with substance use disorder safer.

New study links basal‑prandial insulin to healthier remnant cholesterol in type 2 diabetes, spotlighting hidden cardiovascular risk beyond low-density lipoprotein and A1c.

In a bonus episode of the Over the Counter podcast, William A. Bryson, PharmD, joined to help celebrate Diabetes Alert Day—recognized annually on the fourth Tuesday in March.

This episode highlights the landmark FTC settlement with Express Scripts and what independent pharmacies and plan sponsors can expect going forward.

Many patients struggle with the everyday realities of staying on the medication, which can include uncomfortable adverse effects.

With efforts to further scale naloxone access in US community pharmacies, researchers explore the implementation of a hub-and-spoke distribution model.

Lilly’s once-weekly retatrutide lowers A1C up to 2% and drives nearly 17% weight loss in type 2 diabetes, signaling a powerful triple-agonist shift.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, provides nuance and understanding to the FDA’s recent push to move, essentially, ‘every’ drug to OTC formulation.